Vera Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Vera Therapeutics Inc. is based in SOUTH SAN FRANCISCO, Calif.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-152.15M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.87 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -50.92% |
| Return on Assets (Trailing 12 Months) | -42.67% |
| Current Ratio (Most Recent Fiscal Quarter) | 12.21 |
| Quick Ratio (Most Recent Fiscal Quarter) | 12.21 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.19 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $9.08 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.26 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.75 |
| Diluted Earnings per Share (Trailing 12 Months) | $-3.99 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 63.82M |
| Free Float | 53.42M |
| Market Capitalization | $1.54B |
| Average Volume (Last 20 Days) | 1.34M |
| Beta (Past 60 Months) | 1.22 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 16.30% |
| Percentage Held By Institutions (Latest 13F Reports) | 99.21% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |